ChinaDaily Briefs

Daily Brief China: Haitong Securities Co Ltd (H), Air China Ltd (H), Tencent, Akeso Biopharma Inc, Nameson Holdings, China Jinmao Holdings and more

In today’s briefing:

  • Merger Arb Mondays (14 Oct) – Haitong/GJTA, GA Pack, Henlius, Canvest, Seven & I, Arcadium Lithium
  • Rebound in Int’l Demand & Benign Fuel Prices Could Support Recovery in Chinese Airlines’ Share Perf
  • Quiddity Leaderboard HS Internet & IT: Dec 24 Flow Expectations and Mar 25 Expected ADDs/DELs
  • Akeso Biopharma Placement – The Placing Price Is Not Cheap Despite Positive Business Progress
  • Nameson Holdings (1982 HK): 17% Dividend Yield Can Be Sustained and Improved Long-Term
  • Morning Views Asia: China Jinmao Holdings, Yuexiu Property



Rebound in Int’l Demand & Benign Fuel Prices Could Support Recovery in Chinese Airlines’ Share Perf

By Daniel Hellberg

  • By many metrics, Chinese airlines’ recent performance exceeds pre-Covid levels
  • Medium-Term, ongoing int’l recovery and benign fuel prices can boost margins
  • We believe the airlines could recoup weak relative performance vs Trip.com

Quiddity Leaderboard HS Internet & IT: Dec 24 Flow Expectations and Mar 25 Expected ADDs/DELs

By Janaghan Jeyakumar, CFA

  • The Hang Seng Internet & IT (HSIII) index represents the top 30 stocks related to internet and information technology businesses listed in Hong Kong (HKEX).
  • In this insight, we take a look at our capping flow expectations for the December 2024 index rebal event.
  • We have also presented our index change expectations for the next semiannual index review which will take place in March 2025.

Akeso Biopharma Placement – The Placing Price Is Not Cheap Despite Positive Business Progress

By Xinyao (Criss) Wang

  • HARMONi-2 results are impressive and the overall data is solid and reliable. The NMPA has approved NDA of ebronucimab and sNDA of cadonilimab. Akeso’s fundamentals have indeed undergone positive changes.
  • Akeso’s current market capitalization already partially reflects the positive expectation about the future successful FDA approval of AK112. In our view, the Placing Price is not cheap.
  • When the market value falls back to below RMB45 billion is a more comfortable valuation to buy Akeso, and below RMB35 billion market value provides a golden opportunity. 

Nameson Holdings (1982 HK): 17% Dividend Yield Can Be Sustained and Improved Long-Term

By Sameer Taneja


Morning Views Asia: China Jinmao Holdings, Yuexiu Property

By Leonard Law, CFA

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars